A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection

A Multi-country, Multi-center, Retrospective Chart Review to Describe the Use of Maribavir and Its Effectiveness in Patients With Post-Transplant Cytomegalovirus Infection/Disease

The main aim of this study is to check how effective the treatment with Maribavir has been to remove the CMV viruses from the blood of an adult person with CMV infection after a transplant. Other aims are to learn more about how maribavir is used in normal clinical routine, study the profiles of adults treated with maribavir, and what other treatments have been given, and describe healthcare resources used for CMV management.

Only data already available in the medical records of the participants will be reviewed and collected during this study.

This study will include two main periods of retrospective data collection from medical charts: the pre-index period and the post-index period. The index date is defined as the date of initiation of maribavir dosing, as documented in the medical records. The pre-index period covers the time from the transplant date to the index event, while the post-index period starts at the index event and ends at the date of chart abstraction, death, or loss to follow-up, whichever comes first.

Inclusion criteria:

• Aged greater than or equal to (>=) 18 years at the time of consent or start of chart abstraction in case a consent waiver will be allowed as per local regulation.
• Received an HSCT/SOT.
• Diagnosed with CMV infection/disease any time after the HSCT/SOT date.
• Initiated maribavir at least 4 months before the chart abstraction date (or at time of Central Ethics Committee [CEC]/Local Ethics Committee [LEC] submission as per local regulation).
• Participants with hospital medical chart available, who signed an informed consent form before starting any study procedures (unless waiver is allowed as per local regulation).

Exclusion criteria:

• Participants who do not provide informed consent, where consent is required per country regulations.
• Participants who participated to Clinical Trials investigating maribavir.